1. "Department of Medicine"
Formats
  1. Journal Article (19347)
  2. Meeting Abstract (15822)
  3. Review (1102)
  4. Book Section (924)
  5. Editorial (580)
  6. Research Letter (301)
  7. Conference Paper (299)
  8. Guidelines (285)
  9. Correspondence (226)
  10. Miscellaneous (87)
  11. Book Whole (61)
Groups
  1. Department of Medicine (39034)
  2. Solid Tumor Oncology Division (22035)
  3. Hematologic Malignancies, Division of (13003)
  4. Center for Hematologic Malignancies (10841)
  5. GSK Faculty (10529)
  6. Survivorship Research (9202)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Sergio Giralt (1050)
  4. Miguel-Angel Perales (913)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (642)
  2. 2024 (2141)
  3. 2023 (2451)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2560)

More Years

Publications
  1. Journal of Clinical Oncology (6050)
  2. Blood (3572)
  3. Annals of Oncology (1395)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (890)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6364)
  2. Elsevier Inc. (4610)
  3. American Society of Hematology (3843)
  4. American Association for Cancer Research (2879)
  5. Oxford University Press (2271)
  6. Nature Publishing Group (2080)

More Publishers

Results (39034)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Allogeneic chimeric antigen receptor T-cell products cemacabtagene ansegedleucel/ALLO-501 in relapsed/refractory large B-cell lymphoma: Phase I experience from the ALPHA2/ALPHA clinical studies
    Journal Article

    Locke, F. L.; Munoz, J. L.; Tees, M. T.; Lekakis, L. J.; de Vos, S.; Nath, R.; Stevens, D. A.; Malik, S. A.; Shouse, G. P.; Hamadani, M.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Immune checkpoint combos in metastatic castration-resistant prostate cancer: Where are we going, what are we doing, and why?
    Editorial

    Slovin, S. F.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Intracranial disease control and survival among patients with KRAS-mutant lung adenocarcinoma and brain metastases treated with stereotactic radiosurgery
    Journal Article

    Gaeta, B.; Eichholz, J. E.; Walch, H.; Ilica, A. T.; Boe, L.; Kratochvil, L.; Yu, Y.; Gomez, D. R.; Imber, B. S.; Li, B. T.; more...
    International Journal of Radiation Oncology, Biology, Physics (2025)

    Fulltext@MSK | Save
  • Localized and diffuse tenosynovial giant cell tumor: Real-world results from a patient observational registry
    Journal Article

    Stern, S.; McKenzie, P. F.; Bernthal, N.; O’Neill, S.; Palmerini, E.; Randall, R. L.; Tap, W.; Scharschmidt, T.; Rothschild, S.
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Enfortumab vedotin and pembrolizumab: Redefining the standard of care for previously untreated advanced urothelial cancer
    Review

    Sternschuss, M.; Rosenberg, J. E.
    Future Oncology (2025)

    Fulltext@MSK | Save
  • Congenital melanocytic nevi and risk of melanoma
    Review

    Pastore, L. M.; Valentini, R.; Marghoob, A. A.
    Clinics in Dermatology (2025)

    Fulltext@MSK | Save
  • Tumor immunophenotypic correlates in patients aged 80 years or older with non-small cell lung cancer and outcomes to first-line pembrolizumab in PD-L1 high (≥50%) patients
    Journal Article

    Barrichello, A. P. C.; Elkrief, A.; Ricciuti, B.; Ganta, T.; Marron, T. U.; Wang, X.; Lotter, W.; Lindsay, J.; Santo, V.; Cortellini, A.; more...
    Clinical Lung Cancer (2025)

    Fulltext@MSK | Save
  • A phase two, single-arm, open-label study with dostarlimab monotherapy in participants with untreated stage II/III dMMR/MSI-H Locally advanced rectal cancer (AZUR-1)
    Journal Article

    Cercek, A.; Bachet, J. B.; Capdevila, J.; Starling, N.; Chen, E.; Salvatore, L.; Bando, H.; O'Donnell, S.; Harfst, L.; Szijgyarto, Z.; more...
    Clinical Colorectal Cancer (2025)

    Fulltext@MSK | Save
  • SOHO state of the art updates and next questions: Diffuse large B-cell lymphoma in older adults: A comprehensive review
    Review

    Iyengar, V.; Hamlin, P.; Torka, P.
    Clinical Lymphoma, Myeloma and Leukemia (2025)

    Fulltext@MSK | Save
  • Optimizing postneoadjuvant treatment of residual breast cancer with adjuvant bevacizumab alone, with metronomic or standard-dose chemotherapy: A combined analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE clinical trials
    Journal Article

    Trapani, D.; Jin, Q.; Miller, K. D.; Rugo, H. S.; Reeder-Hayes, K. E.; Traina, T.; Abdou, Y.; Falkson, C.; Abramson, V.; Ligibel, J.; more...
    Clinical Breast Cancer (2025)

    Fulltext@MSK | Save